1.. Introduction {#s1}
================

Naturally, benzophenone nucleus is found in the aerial part of *Gentiana verna* L \[[@RSOS171771C1]\] and *Garcinia cochinchinensis* \[[@RSOS171771C2]\]. Benzophenone-containing molecules are extensively used in medicinal and agriculture fields. Numerous pharmacological properties are associated with this nucleus, such as non-nucleoside reverse transcriptase inhibition \[[@RSOS171771C3]\], antineoplastic, cytotoxic \[[@RSOS171771C4]\], anti-inflammatory \[[@RSOS171771C5]\], antibacterial \[[@RSOS171771C6]\], antimicrotuble \[[@RSOS171771C7]\], antifungal \[[@RSOS171771C8]\], and urease inhibitory activities \[[@RSOS171771C9]\], inhibitory effects at low-density lipoproteins \[[@RSOS171771C10]\], tolemerase inhibitor \[[@RSOS171771C11]\], anti-cancer agent \[[@RSOS171771C12]\], signal transducer and activator of transcription protein inhibitor \[[@RSOS171771C13]\]. In addition to various biological activities, benzophenone skeleton is also known to have a wide range of luminescence properties \[[@RSOS171771C14],[@RSOS171771C15]\]. Benzophenone derivatives have significant use in dyes. This nucleus also exhibits good photo-initiator properties \[[@RSOS171771C16],[@RSOS171771C17]\].

Leishmaniasis is among the neglected diseases and according to the surveys of the World Health Organization, 350 million people are suffering from this. Leishmaniasis is also responsible for a high mortality rate worldwide \[[@RSOS171771C18],[@RSOS171771C19]\]. It is a vector-borne protozoan disease, mainly originated from the bite of sandfly. Leishmaniasis is initiated when parasite is transmitted to human at metacyclic-flagellated promastigote form. The main site of action involves reticulo-endothelial system of the host. Based on symptoms, leishmaniasis appears in diffused, cutaneous, mucosal and visceral (Kala Azar) forms \[[@RSOS171771C20],[@RSOS171771C21]\].

Currently, antileishmanial remedies include antimonial drugs, such as tartaremetic (antimony potassium tartrate), urea stibamine, amphotericin B and pentamidines bisamidine \[[@RSOS171771C22]\]. However, adverse side effects of these chemotherapeutic agents have made their use limited \[[@RSOS171771C23]\].

In the light of a previous report on antileishmanial activities of benzophenone ethers \[[@RSOS171771C24]\], structure of pentamidine which possesses ether functionality ([figure 1](#RSOS171771F1){ref-type="fig"}), and in continuation of our search for antileishmanial agents \[[@RSOS171771C25]--[@RSOS171771C27]\], we have synthesized a library of functionalized benzophenone ethers and evaluated their antileishmanial activities *in vitro*. To the best of our knowledge, compounds **1** and **2** were previously reported, while remaining compounds are new \[[@RSOS171771C28],[@RSOS171771C29]\]. Figure 1.Rationale for the current study.

2.. Results and discussion {#s2}
==========================

2.1.. Chemistry {#s2a}
---------------

4-Hydroxybenzophenone (2 mmol), varyingly substituted aryl halide or phenacyl halide (2 mmol), and potassium carbonate (2 mmol) in the presence of catalytic amount of tetrabutylammonium bromide (TBAB) in dichloromethane (15 ml) were refluxed for 6 h. Progression of reaction was studied by thin layer chromatography (TLC). Reaction mixture was cooled to room temperature and a solid material was obtained. The solid was filtered and washed with hexane followed by drying resulting in the desired compounds in good yields ([scheme 1](#RSOS171771F13){ref-type="fig"}). The characterization of synthetic compounds was carried out by ^1^H and ^13^C nuclear magnetic resonance (NMR), electron impact mass spectrometry (EI-MS), high-resolution EI-MS (HREI-MS) and IR spectroscopy. Scheme 1.Synthesis of benzophenone ethers.

2.2.. Spectroscopic studies on representative (most active) compound, 2-(4-benzoylphenoxy)-1-(3,4-dichlorophenyl)ethanone (18) {#s2b}
------------------------------------------------------------------------------------------------------------------------------

The structure of most active compound (2-(4-benzoylphenoxy)-1-(3,4-dichlorophenyl)ethanone, **18**) was deduced by ^1^H- and ^13^C-NMR spectroscopy which was performed in deuterated dimethylsulfoxide (DMSO-*d*~6~) with a Bruker Avance AM 300 MHz instrument. In ^1^H-NMR spectrum doublet for H-2 and H-6 protons was obtained at *δ*~H~ 7.73 (*J*~2,3/6,5~ = 8.7 Hz). However, one more doublet with integration of two protons at *δ*~H~ 7.64 (*J*~2′,3′/6′,5′~ = 7.2 Hz) was assigned to H-2′ and H-6′. Another proton doublet for H-4 was obtained at *δ*~H~ 7.70 (*J*~4(3,5)~ = 8.7 Hz). A triplet for two protons H-3 and H-5 was obtained at *δ*~H~ 7.56 (*J*~3(2,4)/5(4,6)~ = 8.5 Hz). A doublet at *δ*~H~ 7.88 (*J*~6′′,5′′ ~= 8.4 Hz) was assigned to H-6^‴^. However, singlet at *δ*~H~ 5.74 for CH~2~ group confirmed the existence of ether linkage. In addition, other aromatic protons justified their resonance frequency along with their respective *J* values ([figure 2](#RSOS171771F2){ref-type="fig"}). Figure 2.^1^H-NMR chemical shift values for most active compound **18**.

In broadband decoupled ^13^C-NMR spectra, 16 signals appeared: eight signals are for methines, and seven signals for quaternary carbons. Carbon at *δ*~C~ 70.3 appeared also in spectra: it was for one methylene present in the structure. The most deshielded signals at *δ*~C~ 194.4 and 193.1 were due to carbonylic carbons. Signal at *δ*~C~ 161.6 was due to aromatic cabon directly attached to ether oxygen C-4′. Adjacent to carbonyl groups, three carbons, i.e. (C-1), (C-1′), and (C-1^‴^), resonated at *δ*~C~ 133.5, 133.8 and 130.8, respectively. Rest of the carbons in the structure resonated in the normal aromatic range of *δ*~C~ 132.2--114.6 ([figure 3](#RSOS171771F3){ref-type="fig"}). Figure 3.^13^C-NMR chemical shift values for compound **18**.

High-resolution mass spectrum of compound **18** displayed the M^+^ at *m/z* 384.0321 with a composition of C~21~H~14~Cl~2~O~3~ (calcd 384.0320). The per cent abundance of isotopic \[M + 4\]^+^ 10%, \[M + 2\]^+^ 49% and molecular ion peak M^+^ 76% at *m/z* 388, 386 and 384, respectively, confirmed the presence of two chlorine atoms in a molecule. Cleavage of carbon--carbon bond from *α-*carbonyl group of ether resulted in respective methylene benzophenone ether which appeared at *m/z* 211, and remaining acylium ion appeared as base peak at *m/z* 173. Fragment at *m/z* 198 was due to benzophenone fragment. It was further fragmented into respective acylium ion at *m/z* 121. Fragments at *m/z* 105 and 77 were due to benzyl acylium ion and benzene radical cation, respectively ([figure 4](#RSOS171771F4){ref-type="fig"}). Figure 4.EI-MS fragmentation pattern of compound **18**.

In the Fourier transform IR (FT-IR) spectrum, vibrational frequencies at 1710 and 1628 cm^−1^ correspond to the carbonyl (C=O) functionality. However, vibrational frequencies of aromatic (C=C) bond and ether (C--O) appeared at 1557 and 1309 cm^−1^ ([figure 5](#RSOS171771F5){ref-type="fig"}), respectively. These are spectroscopic observations of proposed structure for compound **18**. Structures of all other compounds were deduced in a similar manner. Figure 5.FT-IR absorptions of compound **18**.

2.3.. Antileishmanial studies {#s2c}
-----------------------------

Twenty 4-substituted ether derivatives of benzophenone (**1**--**20**) were synthesized. Among these, nine were α-substituted carbonyl ether derivatives, while 11 were simple ether derivatives of benzophenone. All the synthetic compounds were screened for antileishmanial activities. Results indicated that aryl or alkyl parts of ether analogues having different substituents are responsible for antileishmanial activities ([figure 6](#RSOS171771F6){ref-type="fig"}; [table 1](#RSOS171771TB1){ref-type="table"}). Figure 6.General structures of 4-substituted ether derivatives of benzophenone. Table 1.Antileishmanicidal activity of benzophenone ethers 1--20 (s.e.m. is the standard error of the mean and n.a. means not active).![](rsos171771-i1.jpg)

### 2.3.1.. 4-Substituted *α*-carbonyl ether analogues of benzophenone {#s2c1}

Among 4-substituted *α*-carbonyl ethers, compound **18** containing chloro groups at *meta* and *para* positions of aryl part was found to be the most active member of series having IC~50~ value of 1.94 ± 0.70 µg ml^−1^. However, the introduction of chloro group at *para* position of aryl part, as in compound **17**, exhibited a decreased inhibitory activity (IC~50~ = 82.3 ± 2.30 µg ml^−1^). Nevertheless, the presence of a bromo functionality at *para* position of aryl part, as in compound **12**, exhibited a weak inhibitory effect (IC~50~ = 53.3 ± 2.6 µg ml^−1^) ([figure 7](#RSOS171771F7){ref-type="fig"}). Figure 7.Structure--activity relationship of halide-substituted aryl part for **12**, **17** and **18**.

When compounds **19**, **20** and **15** were screened for their antileishmanial activities, compound **19** having an unsubstituted aryl part and compound **20** having a methyl group at *para* position of aryl part showed moderate inhibitory effect with IC~50~ value of 27.63 ± 0.38 µg ml^−1^ and 22.78 ± 0.31* *μg ml^−1^, respectively. However, increase of carbon load at aryl part such as placing a *para* phenyl as in analogue **15** resulted in a decreased activity (IC~50~ = 67.2 ± 2.20 µg ml^−1^) ([figure 8](#RSOS171771F8){ref-type="fig"}). Figure 8.Structure--activity relationship in unsubstituted, methyl and phenyl compounds **15**, **19** and **20**.

### 2.3.2.. 4-Substituted ether derivatives of benzophenone {#s2c2}

In 4-substituted ether derivatives, compound **8** having chloro group at *meta* position of aryl part was found to be the second most active member of the series with IC~50~ = 13.11 ± 0.42 µg ml^−1^. Nevertheless, the introduction of chloro substituent to *para* position, as in **9** (IC~50~ = 17.02 ± 0.70 µg ml^−1^), showed a slight decreased activity. When a dichloro substituent was present at *meta* and *para* positions of aryl part, as in compound **5**, a sharp decline (IC~50~ = 63.3 ± 3.30 µg ml^−1^) in activity was observed ([figure 9](#RSOS171771F9){ref-type="fig"}). Figure 9.Structure--activity relationship of chloro-substituted compounds **5**, **8** and **9**.

However, the presence of a chloro group at *ortho* and a fluoro group at *para* as in compound **6** demonstrated a weak inhibitory activity having an IC~50~ value of 65.0 ± 5.00 µg ml^−1^. Moreover, a bromo substituent at *ortho* position, as in compound **3**, made it weakly active with an IC~50~ value of 68.75 ± 6.20 µg ml^−1^ ([figure 10](#RSOS171771F10){ref-type="fig"}). Figure 10.Structure--activity relationship of chloro-, fluoro- and bromo-substituted compounds **3** and **6**.

The presence of methoxy group at *meta* position as in molecule **11** made it fairly active (IC~50 ~= 30.43 ± 0.50 µg ml^−1^). Replacement of methoxy substituent with a methyl substituent at *meta* position of aryl part as in derivative **10** displayed a good activity (IC~50~ = 13.59 ± 0.28 µg ml^−1^). However, when switching the methyl group to *para* position of aryl part as in analogue **7** (IC~50~ = 77.5 ± 2.50 µg ml^−1^), a weak inhibitory activity was observed ([figure 11](#RSOS171771F11){ref-type="fig"}). Figure 11.Structure--activity relationship of alkoxy- and alkyl-substituted compounds **7**, **10** and **11**.

To study the effect of carbon load, compound **1** having a propyl group at ether part was screened and found to have a weak activity with an IC~50~ value of 70.6 ± 2.3* *μg ml^−1^. But, remaining derivatives were found to be inactive ([figure 12](#RSOS171771F12){ref-type="fig"}). Figure 12.Structure--activity relationship of 4-ether-substituted compound **1**.

3.. Conclusion {#s3}
==============

This study deals with the synthesis of 20 4-substituted ethers of benzophenone derivatives and their antileishmanial activities were screened. Fifteen compounds displayed antileishmanial activity having IC~50~ values within the range of 1.94--82.30 μg ml^−1^. Compound **18** was found to be the most active compound (IC~50~ = 1.94 µg ml^−1^) of this series. These compounds seemingly have potential to develop powerful antileishmanial agents.

4.. Experimental procedure {#s4}
==========================

4.1.. Material and methods {#s4a}
--------------------------

TBAB, 4-hydroxybenzophenone, potassium carbonate, different phenacyl halide and aryl halides were acquired from TCI (Japan). RPMI 1640 Liquid 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), with [l]{.smallcaps}-glutamine without NaHCO~3~ was purchased from Sigma-Aldrich (USA). Neubauer counting chamber (2.5 × 10^−3^ mm^2^) was obtained from Marienfeld, Germany. *Leishmania major* was obtained from DESTO. Fetal bovine serum (Cat No. S181H-100 and Lot No. S11302S181H) was acquired from Biowest (The Serum Specialist), and standard drug pentamidine was obtained from Merck. 2-Amino-5-benzonitrile, *N,N*-dimethylformamide 1,1-dimethoxyethane and acetic acid-substituted anilines were purchased from TCI (Japan). All chemicals were used as received without purification. TLC analysis was performed on pre-coated silica gel aluminium cards (Kieselgel 60, 254, E. Merck, Germany). UV lamp at 254 and 365 nm was employed for the visualization of TLC chromatograms.

Mass spectra were recorded with a Finnigan MAT-311A (Germany) mass spectrometer. ^1^H- and ^13^C-NMR spectra were recorded with Bruker Avance AM 300 and 400 MHz spectrometers. Melting points of the compounds were determined using a Stuart^®^ SMP10 melting point apparatus, and are uncorrected. IR spectra (KBr discs) were recorded with a FTS 3000 MX, Bio-RAD Merlin (Excalibur Model) spectrophotometer.

4.2.. Antileishmanial assay protocol {#s4b}
------------------------------------

*Leishmania major* (MHOM/Pk/88/DESTO) was performed in bulk in modified *N,N,N*-biphasic medium by means of normal physiological saline. *Leishmania major* (MHOM/Pk/88/DESTO) promastigotes were grown in the RPMI 1640 medium (Sigma, St Louis, USA), supplemented with 10% heat-inactivated fetal calf serum (PAA Laboratories GmbH, Austria). Parasites at log phase were centrifuged at 2000 r.p.m. for 10 min and at the same speed and washed time three times with saline. Parasites were diluted to a final density of 1 × 10^6^ cells ml^−1^ with a fresh culture medium.

The assay was carried out in a 96-well micro-titre plate; the medium was added in different wells. The test compound (20 µl) was added in the medium and serially diluted. Parasite culture (100 µl) was added in all wells. Two rows were left for positive and negative controls. In positive controls, different quantities of standard antileishmanial drug pentamidine (ICN Biomedical Inc, USA) were present, while negative controls contained only medium. The plate was incubated for 72 h at 22--25°C. The culture was microscopically examined on Neubauer counting chamber. IC~50~ values were calculated by software Ezfit 5.03 (Perella Scientific, USA). All tests were carried out three times \[[@RSOS171771C30]\].

4.3.. General procedure for the synthesis of compounds 1--20 {#s4c}
------------------------------------------------------------

Differently substituted benzophenone ethers were synthesized by refluxing a mixture of 4-hydroxybenzophenone, potassium carbonate, TBAB, differently substituted phenacyl halide and aryl/alkyl halide in dichloromethane as solvent. The reaction was examined by TLC. Subsequently, the reaction mixture was filtered, and cooled until precipitates became visible. These precipitates were sieved and rinsed with hexane. Yield of all the synthetic compounds was moderate to high.

4.4.. Spectral data of synthetic compounds 1--20 {#s4d}
------------------------------------------------

### 4.4.1.. Phenyl(4-propoxyphenyl)methanone (1) {#s4d1}

Yield: 81%; m.p. 91--93°C; R*~f~*: 0.51 (ethyl acetate/hexanes, 2:8); IR (KBr, cm^−1^): 3272 (=C--H), 1645 (C=O), 1599 (C=C), 1257 (C--O); ^1^H-NMR (300 MHz, DMSO-*d~6~*): *δ*~H~ 7.79 (d, 2H, *J*~2,3/6,5~ = 8.7 Hz, H-2, H-6), 7.71 (d, 2H, *J*~2′,3′/6′,5′~ = 6.9 Hz, H-2′, H-6′), 7.63 (t, 1H, *J*~4(3,5)~ = 8.1 Hz, H-4), 7.53 (t, 2H, *J*~3(2,4)/5(6,4)~ = 7.8 Hz, H-3, H-5), 7.03 (d, 2H, *J*~3′,2′/5′,6′~ = 8.7 Hz, H-3′, H-5′), 4.05 (t, 2H, *J*~(CH2,CH2)~ = 6.6 Hz, CH~2~), 1.88 (m, 2H, CH~2~), 1.081 (t, 3H, *J*~(CH3,CH2)~ = 7.5 Hz, CH~3~); EI-MS: *m/z* (rel. abund.%), 240 \[M\]^+^ (51.0), 198 (20.0), 163 (9.6), 121 (100.0), 105 (14.5), 77 (7.7); HREI-MS: *m/z* calcd for C~16~H~16~O~2~ \[M\]^+^ 240.1150, found 240.1151.

### 4.4.2.. (4-(Benzyloxy)phenyl)(phenyl)methanone (2) {#s4d2}

Yield: 82%; m.p. 90--92°C; R*~f~*: 0.50 (ethyl acetate/hexanes, 2:8); IR (KBr, cm^−1^): 3273 (=C--H), 1641 (C=O), 1597 (C=C), 1242 (C--O); ^1^H-NMR (300 MHz, DMSO-*d~6~*): *δ*~H~ 7.75 (d, 2H, *J*~2,3/6,5~ = 8.7 Hz, H-2, H-6), 7.69 (m, 3H, H-2^′′^, H-4^′′^, H-6^′′^), 7.56 (t, 2H, *J*~3(2,4)/5(4,6)~ = 7.8 Hz, H-3, H-5), 7.48 (d, 2H, *J*~2′,3′/6′,5′~ = 6.9 Hz, H-2′, H-6′), 7.42 (m, 3H, H-4, H-3^′′^, H-5^′′^), 7.18 (d, 2H, *J*~3′,2′/5′,6′~ = 8.7 Hz, H-3′, H-5′), 5.21 (s, 2H, CH~2~); ^13^C-NMR (125.0 MHz, DMSO-*d*~6~): *δ*~C~ 194.3 (C=O), 162.0 (C-4′), 137.7 (C-4), 136.4 (C-1), 132.1 (C-1^′′^), 132.0 (C-1′), 129.5 (C-2′, C-6′), 129.2 (C-2, C-6), 128.5 (C-2^′′^, H-6^′′^), 128.4 (C-3, C-5), 128.0 (C-3^′′^, C-5^′′^), 127.7 (C-4^′′^), 114.6 (C-3′, C-5′), 69.5 (CH~2~); EI-MS: *m/z* (rel. abund.%), 288 \[M\]^+^ (46.9), 211 (1.4), 198 (4.1), 181 (1.3), 141 (7.0), 121 (8.3), 115 (6.6), 105 (19.7), 91 (100.0), 77 (28.2); HREI-MS: *m/z* calcd for C~20~H~16~O~2~ \[M\]^+^ 288.1150, found 288.1140.

### 4.4.3.. (4-(2-Bromobenzyloxy)phenyl)(phenyl)methanone (3) {#s4d3}

Yield: 84%; m.p. 96--98°C; R*~f~*: 0.47 (ethyl acetate/hexanes, 2:8); IR (KBr, cm^−1^): 3261 (=C--H), 1703 (C=O), 1637 (C=C), 1265 (C--O), 704 (=C--Br); ^1^H-NMR (300 MHz, DMSO-*d~6~*): *δ*~H~ 7.77 (d, 2H, *J*~2,3/6,5~ = 8.7 Hz, H-2, H-6), 7.70 (d, 2H, *J*~2′,3′/6′,5′/3′′,4′′~ = 8.1 Hz, H-2′, H-6′, H-3^′′^), 7.65 (t, 2H, *J*~3(2,4)/5(4,6)~ = 6.9 Hz, H-3, H-5), 7.56 (m, 2H, H-4, H-6^′′^), 7.47 (t, 1H, *J*~5′′\ (4′′,6′′)~ = 7.2 Hz, H-5′′), 7.36 (t, 1H, *J*~4′′\ (3′′,5′′)~ = 7.5 Hz, H-4~′′~), 7.20 (d, 2H, *J*~3′,2′/5′,6′~ = 8.7 Hz, H-3′, H-5′), 5.23 (s, 2H, CH~2~); ^13^C-NMR (125.0 MHz, DMSO-*d*~6~): *δ*~C~ 194.4 (C=O), 161.8 (C-4′), 137.6 (C-4), 135.2 (C-1), 132.7 (C-1′′), 132.2 (C-1′), 132.1 (C-2′, C-6′), 130.5 (C-2, C-6), 130.4 (C-3, C-5), 129.8 (C-3′, C-5′), 129.3 (C-2′′), 128.4 (C-6′′), 128.0 (C-3′′), 123.0 (C-5′′), 114.6 (C-4^′′^), 69.4 (CH~2~); EI-MS: *m/z* (rel. abund.%), 368 \[M + 2\]^+^ (8.7), 366 \[M\]^+^ (8.7), 287 (1.7), 197 (1.0), 181 (0.2), 167 (95.0), 169 (100.0), 152 (1.3), 105 (9.4), 90 (21.7), 77 (11.9); HREI-MS: *m/z* calcd for C~20~H~15~BrO~2~ \[M\]^+^ 366.0255, found 366.0252.

### 4.4.4.. (4-(4-Nitrobenzyloxy)phenyl)(phenyl)methanone (4) {#s4d4}

Yield: 85%; m.p. 135--137°C; R*~f~*: 0.46 (ethyl acetate/hexanes, 2 : 8); IR (KBr, cm^--1^): 3072 (=C--H), 1641 (C=O), 1602 (C=C), 1515 (N=O), 1255 (C--O); ^1^H-NMR (300 MHz, DMSO-*d~6~*): *δ*~H~ 8.28 (d, 2H, *J*~3′′,2′′/5′′,6′′~ = 8.4 Hz, H-3′′, H-5′′), 7.77 (m, 4H, H-2′, H-3′, H-5′, H-6′), 7.69 (m, 3H, H-2, H-4, H-6), 7.56 (t, 2H, *J*~3(2,4)/5(4,6)~ = 7.5 Hz, H-3, H-5), 7.20 (d, 2H, *J*~3′,2′/5′,6′~ = 8.7 Hz, H-3′, H-5′), 5.40 (s, 2H, CH~2~); ^13^C-NMR (125.0 MHz, DMSO-*d*~6~): *δ*~C~ 194.4 (C=O), 161.5 (C-4′), 147.1 (C-4′′), 144.3 (C-4), 137.6 (C-1′′), 132.2 (C-1′), 129.8 (C-1), 129.2 (C-2′, C-6′), 128.4 (C-2, C-6), 128.3 (C-3, C-5), 123.4 (C-2′′, C-6′′), 123.6 (C-3′, C-5′), 114.7 (C-3′′, C-5′′), 69.4 (CH~2~); EI-MS: *m/z* (rel. abund.%), 333 \[M\]^+^ (43.2), 287 (1.0), 256 (4.1), 197 (30.5), 169 (10.6), 136 (89.7), 106 (74.4), 77 (100.0); HREI-MS: *m/z* calcd for C~20~H~15~NO~4~ \[M\]^+^ 333.1001, found 333.1014.

### 4.4.5.. (4-(3,4-Dichlorobenzyloxy)phenyl)(phenyl)methanone (5) {#s4d5}

Yield: 83%; m.p. 142--145°C; R*~f~*: 0.47 (ethyl acetate/hexanes, 2:8); IR (KBr, cm^−1^): 3255 (=C--H), 1641 (C=O), 1600 (C=C), 1257 (C--O), 810 (=C--Cl); ^1^H-NMR (300 MHz, DMSO-*d~6~*): *δ*~H~ 8.28 (d, 3H, *J*~2,3/6,5/6′′,5′′~ = 8.4 Hz, H-3′′, H-5′′), 7.69 (t, 2H, *J*~3(2,4)/4(3,5)/5(4,6)~ = 7.5 Hz, H-3, H-4, H-5), 7.56 (m, 3H, H-2′, H-6′, H-2′′), 7.18 (d, 2H, *J*~3′,2′/5′,6′~ = 8.7 Hz, H-3′, H-5′), 5.23 (s, 2H, CH~2~); ^13^C-NMR (75.0 MHz, DMSO-*d*~6~): *δ*~C~ 194.3 (C=O), 161.6 (C-4′), 137.7 (C-4′′), 137.6 (C-1′′), 132.1 (C-1′), 131.1 (C-1), 130.7 (C-3′′), 130.5 (C-4), 129.8 (C-2, C-6), 129.6 (C-2′, C-6′), 129.2 (C-2′′), 128.4 (C-5′′), 127.9 (C-6′′), 127.5 (C-3, C-5), 114.7 (C-3′, C-5′), 67.9 (CH~2~); EI-MS: *m/z* (rel. abund.%), 356 \[M\]^+^ (2.3), 198 (0.2), 159 (100.0), 141 (6.5), 123 (15.3), 105 (11.5), 91 (1.6), 77 (39.7); HREI-MS: *m/z* calcd for C~20~H~14~Cl~2~O~2~ \[M\]^+^ 356.0371, found 356.0370.

### 4.4.6.. (4-(2-Chloro-4-fluorobenzyloxy)phenyl)(phenyl)methanone (6) {#s4d6}

Yield: 82%; m.p. 88--90°C; R*~f~*: 0.45 (ethyl acetate/hexanes, 2:8); IR (KBr, cm^−1^): 3255 (=C--H), 1641 (C=O), 1600 (C=C), 1257 (C--O), 810 (=C--Cl); ^1^H-NMR (300 MHz, DMSO-*d~6~*): *δ*~H~ 8.28 (d, 2H, *J*~2,3/6,5~ = 8.4 Hz, H-2, H-6), 8.26 (s, 1H, H-3′′), 7.69 (t, 3H, *J*~3(2,4)/4(3,5)/5(4,6)~ = 7.5 Hz, H-3, H-4, H-5), 7.56 (m, 4H, H-2′, H-6′, H-5′′, H-6′′), 7.18 (d, 2H, *J*~3′,2′/5′,6′~ = 8.7 Hz, H-3′, H-5′), 5.23 (s, 2H, CH~2~); ^13^C-NMR (75.0 MHz, DMSO-*d*~6~): *δ*~C~ 194.3 (C=O), 161.6 (C-4′), 137.7 (C-4′′), 137.6 (C-1′′), 132.1 (C-1′), 131.1 (C-1), 130.7 (C-3′′), 130.5 (C-4), 129.8 (C-2, C-6), 129.6 (C-2′, C-6′), 129.2 (C-2′′), 128.4 (C-5′′), 127.9 (C-6′′), 127.5 (C-3, C-5), 114.7 (C-3′, C-5′), 67.9 (CH~2~); EI-MS: *m/z* (rel. abund.%), 342 \[M + 2\]^+^ (2.0) 340 \[M\]^+^ (5.4), 145 (53.6), 143 (100.0), 141 (6.5), 108 (9.0), 107 (20.8), 105 (9.8) 91 (1.6), 77 (28.4); HREI-MS: *m/z* calcd for C~20~H~14~ClFO~2~ \[M\]^+^ 340.0666, found 340.0667.

### 4.4.7.. (4-(4-Methylbenzyloxy)phenyl)(phenyl)methanone (7) {#s4d7}

Yield: 85%; m.p. 102--104°C; R*~f~*: 0.48 (ethyl acetate/hexanes, 2:8); IR (KBr, cm^−1^): 3091 (=C--H), 1654 (C=O), 1593 (C=C), 1147 (C--O); ^1^H-NMR (300 MHz, DMSO-*d~6~*): *δ*~H~7.74 (d, 2H, *J*~2,3/6,5~ = 8.7 Hz, H-2, H-6), 7.68 (d, 2H, *J*~2′,3′/6′,5′~ = 7.2 Hz, H-2′, H-6′), 7.64 (d, 1H, *J*~4(3,5)~ = 6.3 Hz, H-4), 7.56 (t, 2H, *J*~3(2,4)/5(4,6)~ = 7.5 Hz, H-3, H-5), 7.36 (d, 2H, *J*~3′,2′/5′,6′~ = 8.1 Hz, H-3′, H-5′), 7.21 (d, 2H, *J*~3′′,2′′/5′′,6′′~ = 7.8 Hz, H-3′′, H-5′′), 7.16 (d, 2H, *J*~2′′,3′′/6′′,5′′~ = 8.7 Hz, H-2′′, H-6′′), 5.16 (s, 2H, CH~2~), 2.30 (s, 3H, 4′′-CH~3~); ^13^C-NMR (75.0 MHz, DMSO-*d*~6~): *δ*~C~ 194.5 (C=O), 162.0 (C-4′), 137.7 (C-4′′), 137.3 (C-1′′), 133.3 (C-1′), 132.1 (C-1), 132.0 (C-4), 129.4 (C-2, C-6), 129.2 (C-2′, C-6′), 129.0 (C-2′′, C-6′′), 128.4 (C-3, C-5), 127.9 (C-3′′, C-5′′), 114.6 (C-3′, C-5′), 69.4 (CH~2~), 20.7 (4′′-CH~3~); EI-MS: *m/z* (rel. abund.%), 302 \[M\]^+^ (11.5), 209 (35.1), 198 (22.5), 179 (5.8), 141 (6.1), 121 (36.6), 105 (100.0), 91 (7.7), 77 (16.8); HREI-MS: *m/z* calcd for C~21~H~18~O~2~ \[M\]^+^ 302.1307, found 302.1305.

### 4.4.8.. (4-(3-Chlorobenzyloxy)phenyl)(phenyl)methanone (8) {#s4d8}

Yield: 81%; m.p. 128--130°C; R*~f~*: 0.46 (ethyl acetate/hexanes, 2:8); IR (KBr, cm^−1^): 3100 (=C--H), 1660 (C=O), 1598 (C=C), 1197 (C--O); ^1^H-NMR (400 MHz, DMSO-*d~6~*): *δ*~H~7.76 (d, 2H, *J*~2,3/6,5~ = 10.0 Hz, H-2, H-6), 7.69 (m, 3H, H-3, H-4, H-5), 7.56 (m, 3H, H-2′, H-6′, H-2′′), 7.45 (m, 3H, H-4′′, H-5′′, H-6′′), 7.18 (d, 2H, *J*~3′,2′/5′,6′~ = 11.6 Hz, H-3′, H-5′), 5.23 (s, 2H, CH~2~); EI-MS: *m/z* (rel. abund. %), 322 \[M\]^+^ (11.8), 169 (10.6), 141 (18.2), 125 (100.0), 89 (23.9), 77 (25.9); HREI-MS: *m/z* calcd for C~20~H~15~ClO~2~ \[M\]^+^ 322.0761, found 322.0762.

### 4.4.9.. (4-(4-Chlorobenzyloxy)phenyl)(phenyl)methanone (9) {#s4d9}

Yield: 81%; m.p. 130--132°C; R*~f~*: 0.47 (ethyl acetate/hexanes, 2:8); IR (KBr, cm^−1^): 3125 (=C--H), 1670 (C=O), 1634 (C=C), 1278 (C--O), 878 (=C--Cl); ^1^H-NMR (400 MHz, DMSO-*d~6~*): *δ*~H~ 7.75 (d, 2H, *J*~2,3/6,5~ = 8.8 Hz, H-2, H-6), 7.68 (d, 2H, *J*~2′,3′/6′,5′~ = 7.2 Hz, H-2′, H-6′), 7.64 (d, 1H, *J*~4(3,5)~ = 7.2 Hz, H-4), 7.55 (d, 2H, *J*~3′′,2′′/5′′,6′′ ~= 7.6 Hz, H-3′′, H-5′′), 7.51 (t, 2H, *J*~3\ (2,4)/5\ (4,6)~ = 7.6 Hz, H-3, H-5) 7.48 (d, 2H, *J*~2′′,3′′/6′′,5′′~ = 7.2 Hz, H-2′′, H-6′′), 7.52 (d, 2H, *J*~3′,2′/5′,6′~ = 8.8 Hz, H-3′, H-5′), 5.14 (s, 2H, CH~2~); ^13^C-NMR (100 MHz, DMSO-*d*~6~): *δ*~C~ 194.4 (C=O), 161.8 (C-4′), 137.7 (C-1), 135.5 (C-1′), 132.6 (C-1′′), 132.2 (C-2, C-6), 132.1 (C-2′′, C-6′′), 129.7 (C-3, C-5), 129.6 (C-3′′, C-5′′), 129.2 (C-4), 128.5 (C-4′′), 128.4 (C-2′, C-6′), 114.7 (C-3′, C-5′), 68.7 (CH~2~); EI-MS: *m/z* (rel. abund. %), 324 \[M + 2\]^+^ (1.9), 322 \[M\]^+^ (6.1), 125 (100.0), 105 (3.2), 89 (6.7), 78 (8.6); HREI-MS: *m/z* calcd for C~20~H~15~ClO~2~ \[M\]^+^ 322.0761, found 322.0760.

### 4.4.10.. (4-(4-Methylbenzyloxy)phenyl)(phenyl)methanone (10) {#s4d10}

Yield: 86%; m.p. 106--108°C; R*~f~*: 0.49 (ethyl acetate/hexanes, 2:8); IR (KBr, cm^−1^): 3090 (=C--H), 1665 (C=O), 1578 (C=C), 1167 (C--O); ^1^H-NMR (400 MHz, DMSO-*d~6~*): *δ*~H~ 7.75 (d, 2H, *J*~2,3/6,5~ = 8.4 Hz, H-2, H-6), 7.68 (d, 2H, *J*~2′,3′/6′,5′~ = 7.2 Hz, H-2′, H-6′), 7.64 (d, 1H, *J*~4(3,5)~ = 7.2 Hz, H-4), 7.55 (t, 2H, *J*~3\ (2,4)/5\ (4,6)~ = 7.6 Hz, H-3, H-5), 7.28 (m, 2H, H-3′, H-5′), 7.17 (d, 3H, *J*~4′′(5′′,6′′)/5′′,4′′/6′′,5′′~ = 8.8 Hz, H-4′′, H-5′′, H-6′′), 5.17 (s, 2H, CH~2~), 2.31 (s, 3H, 3′′-CH~3~); EI-MS: *m/z* (rel. abund.%), 302 \[M\]^+^ (0.9), 141 (3.9), 121 (5.4), 115 (3.2), 105 (100.0), 77 (34.1), 63 (9.2), 51 (4.8); HREI-MS: *m/z* calcd for C~21~H~18~O~2~ \[M\]^+^ 302.1307, found 302.1305.

### 4.4.11.. (4-(3-Methoxybenzyloxy)phenyl)(phenyl)methanone (11) {#s4d11}

Yield: 83%; m.p. 120--122°C; R*~f~*: 0.44 (ethyl acetate/hexanes, 2:8); IR (KBr, cm^−1^): 3150 (=C--H), 1689 (C=O), 1550 (C=C), 1157 (C--O); ^1^H-NMR (300 MHz, DMSO-*d~6~*): *δ*~H~ 7.74 (d, 2H, *J*~2,3/6,5~ = 8.8 Hz, H-2, H-6), 7.68 (d, 2H, *J*~2′,3′/6′,5′~ = 8.4 Hz, H-2′, H-6′), 7.64 (d, 1H, *J*~6′′,5′′~ = 7.2 Hz, H-6′′) 7.55 (t, 2H, *J*~3\ (2,4)/5\ (4,6)~ = 7.6 Hz, H-3, H-5), 7.33 (t, 1H, *J*~4(3,5)~ = 7.2 Hz, H-4), 7.17 (d, 2H, *J*~3′,2′/5′,6′~ = 8.4 Hz, H-3′, H-5′), 7.03 (m, 2H, H-2′′, H-5′′), 6.91 (dd, 1H, *J*~4′′,5′′ ~= 6.4 Hz, *J*~4′′,2′′ ~= 1.6 Hz, H-4′′); EI-MS: *m/z* (rel. abund. %), 318 \[M\]^+^ (74.4), 211 (4.2), 198 (6.4), 169 (2.3), 141 (4.2), 121 (100.0), 105 (16.0), 91 (38.8), 77 (28.1); HREI-MS: *m/z* calcd for C~21~H~18~O~3~ \[M\]^+^ 318.1256, found 318.1255.

### 4.4.12.. 2-(4-Benzoylphenoxy)-1-(4-bromophenyl)ethanone (12) {#s4d12}

Yield: 82%; m.p. 126--128°C; R*~f~*: 0.47 (ethyl acetate/hexanes, 2:8); IR (KBr, cm^−1^): 3390 (=C--H) 1703 (C=O), 1637 (C=O), 1593 (C=C), 1315 (C--O), 560 (=C--Br); ^1^H-NMR (300 MHz, DMSO-*d~6~*): *δ*~H~ 7.79 (d, 2H, *J*~2′′,3′′/6′′,5′′~ = 8.4 Hz, H-2′′, H-6′′), 7.81 (d, 2H, *J*~3′′,2′′/5′′,6′′~ = 8.4 Hz, H-3′′, H-5′′), 7.73 (m, 5H, H-2, H-4, H-6, H-2′, H-6′), 7.56 (t, 2H, *J*~3(2,4)/5(4,6)~ = 7.2 Hz, H-3, H-5), 7.71 (d, 2H, *J*~3′,2′/5′,6′~ = 8.7 Hz, H-3′, H-5′), 5.71 (s, 2H, CH~2~); ^13^C-NMR (100 MHz, DMSO-*d*~6~): *δ*~C~ 194.4 (C=O), 193.2 (C=O), 161.6 (C-4′), 137.6 (C-1), 133.2 (C-1′), 132.1 (C-1′′), 132.0 (C-2, C-6), 131.9 (C-2′′, C-6′′), 129.9 (C-3, C-5), 129.7 (C-3′′, C-5′′), 129.2 (C-4), 128.4 (C-4′′), 128.0 (C-2′, C-6′), 114.6 (C-3′, C-5′), 70.2 (CH~2~); EI-MS: *m/z* (rel. abund.%), 396 \[M^+^+2\] (3.8), 394 \[M\]^+^ (3.9), 376 (4.7), 332 (7.7), 239 (7.5), 180 (100.0), 166 (95.3), 155 (3.5), 77 (44.9); HREI-MS: *m/z* calcd for C~21~H~15~BrO~3~ \[M\]^+^ 394.0205, found 394.0203.

### 4.4.13.. 2-(4-Benzoylphenoxy)-1-(4-nitrophenyl)ethanone (13) {#s4d13}

Yield: 84%; m.p. 113--115°C; *R~f:~* 0.49 (Ethyl acetate/hexane, 3 : 7); IR (KBr, cm^−1^): 3393 (=C--H) 1709 (C=O), 1620 (C=O), 1598 (C=C), 1311 (C--O), 760 (N--O); ^1^H-NMR (300 MHz, DMSO-*d~6~*): *δ* 8.40 (d, 2H, *J*~3′′,2′′/5′′,6′′~= 7.5 Hz, H-3′′,H-5′′), 8.27 (d, 2H, *J*~2′′,3′′/6′′,5′′~= 7.5 Hz, H-2′′,H-6′′), 7.74 (d, 2H, *J*~3′,2′/5′,6′ ~= 7.5 Hz, H-3′,H-5′), 7.70 (m, 2H, H-3, H-5), 7.64 (m, 1H, H-4), 7.56 (m, 2H, H-2,H-6), 7.17 (d, 2H, *J*~2′,3′/6′,5′~= 7.5 Hz, H-2′, H-6′), 5.80 (s, 2H, CH~2~); EI-MS: *m/z* (rel. abund.%), 361.1 \[M\]^+^ (41.0), 345 (1.6), 284 (16.6), 211 (17.8), 198 (39.9), 181 (11.2), 150 (100.0), 121 (77.7), 105 (65.9), 77 (42.3); HREI-MS: *m/z* calcd for C~21~H~15~NO~5~ \[M\]^+^ 361.0950, found 361.0952.

### 4.4.14.. 2-(4-Benzoylphenoxy)-1-(3-methoxyphenyl)ethanone (14) {#s4d14}

Yield: 84%; m.p. 153--156°C; R*~f~*: 0.46 (ethyl acetate/hexanes, 2:8); IR (KBr, cm^−1^): 3377 (=C--H), 1697 (C=O), 1635 (C=O), 1598 (C=C), 1313 (C--O); ^1^H-NMR (300 MHz, DMSO-*d~6~*): *δ*~H~ 7.73 (m, 4H, H-2, H-3, H-5, H-6), 7.64 (d, 2H, *J*~2′,3′/6′,5′~ = 8.4 Hz, H-2′, H-6′), 7.56 (m, 4H, H-2′′, H-4′′, H-5′′, H-6′′), 7.28 (d, 1H, *J*~4(3,5)~ = 6.6 Hz, H-4), 7.13 (t, 2H, *J*~3′(2′,4′)/5′(4′,6′)~ = 8.7 Hz, H-3′, H-5′), 5.73 (s, 2H, CH~2~), 3.83 (s, 3H, 3′′-OCH~3~); ^13^C-NMR (100 MHz, DMSO-*d*~6~): *δ*~C~ 194.4 (C=O), 193.8 (C=O), 161.7 (C-4′), 159.5 (C-3′′), 137.7 (C-1), 135.5 (C-1′′), 132.1 (C-1′), 132.0 (C-2, C-6), 130.0 (C-4), 129.7 (C-3, C-5), 129.2 (C-2′, H-6′), 128.4 (C-2′′), 120.3 (C-5′′), 119.8 (C-2′′), 114.4 (C-6′′), 112.3 (C-4′′), 70.3 (CH~2~), 55.4 (3′′-OCH~3~); EI-MS: *m/z* (rel. abund.%), 346 \[M\]^+^ (18.5), 209 (2.6), 198 (7.8), 150 (2.7), 135 (100.0), 121 (15.8), 107 (19.1), 92 (4.1), 77 (12.0); HREI-MS: *m/z* calcd for C~22~H~18~O~4~ \[M\]^+^ 346.1205, found 346.1224.

### 4.4.15.. 2-(4-Benzoylphenoxy)-1-(biphenyl-4-yl)ethanone (15) {#s4d15}

Yield: 88%; m.p. 100--102°C; R*~f~*: 0.50 (ethyl acetate/hexanes, 2:8); IR (KBr, cm^−1^): 3376 (=C--H), 1692 (C=O), 1636 (C=O), 1589 (C=C), 1310 (C--O); ^1^H-NMR (300 MHz, DMSO-*d~6~*): *δ*~H~ 8.13 (d, 2H, *J*~2′′,3′′/6′′,5′′~ = 8.4 Hz, H-2′′, H-6′′), 7.89 (d, 2H, *J*~2,3/6,5~ = 8.4 Hz, H-2, H-6), 7.78 (m, 7H, H-3, H-4, H-5, H-2′, H-6′, H-3′′, H-5′′), 7.56 (m, 4H, H-3′, H-5′, H-3‴, H-5‴), 7.46 (d, 1H, *J*~4‴(3‴,5‴)~ = 8.7 Hz, H-4‴), 7.15 (d, 2H, *J*~2‴,3‴/6‴,5‴~ = 9.0 Hz, H-2‴, H-6‴), 5.77 (s, 2H, CH~2~); ^13^C-NMR (75.0 MHz, DMSO-*d*~6~): *δ*~C~ 194.4 (C=O), 193.5 (C=O), 161.7 (C-4′), 145.2 (C-1‴), 138.7 (C-1), 137.7 (C-1′), 133.0 (C-4), 132.1 (C-2, C-6), 132.0 (C-2′, C-6′), 129.7 (C-2′′, C-6′′), 129.2 (C-3′′, H-5′′), 129.1 (C-2‴, C-6^‴^), 128.6 (C-3^‴^, C-5^‴^), 128.5 (C-1′), 128.4 (C-4^‴^), 127.3 (C-3, C-5), 127.0 (C-3′, C-5′), 114.6 (C-4′′), 70.3 (CH~2~); EI-MS: *m/z* (rel. abund.%), 392 \[M\]^+^ (11.6), 315 (0.8), 287 (0.2), 211 (0.2), 181 (100.0), 152 (63.4), 115 (0.9), 105 (39.8), 77 (55.9); HREI-MS: *m/z* calcd for C~27~H~20~O~3~ \[M\]^+^ 394.1412, found 392.1413.

### 4.4.16.. 2-(4-Benzoylphenoxy)-1-(4-methoxyphenyl)ethanone (16) {#s4d16}

Yield: 84%; m.p. 145--147°C; R*~f~*: 0.47 (ethyl acetate/hexanes, 2:8); IR (KBr, cm^−1^): 3372 (=C--H), 1690 (C=O), 1636 (C=O), 1158 (C=C), 1310 (C--O); ^1^H-NMR (300 MHz, DMSO-*d~6~*): *δ*~H~ 8.02 (d, 2H, *J*~2,3/6,5~ = 8.7 Hz, H-2, H-6), 7.73 (m, 4H, H-2′, H-3′, H-5′, H-6′), 7.64 (d, 1H, *J*~4(3,5)~ = 8.7 Hz, H-4), 7.56 (t, 2H, *J*~3′(2′,4′)/5′(4′,6′)~ = 8.7 Hz, H-3′, H-5′), 7.10 (d, 4H, *J*~2′′,3′′/3′′,2′′/6′′,5′′/5′′,6′′)~ = 8.7 Hz, H-2^′′^, H-3^′′^, H-5^′′^, H-6^′′^), 5.77 (s, 2H, CH~2~), 3.85 (4′′-OCH~3~); ^13^C-NMR (75.0 MHz, DMSO-*d*~6~): *δ*~C~ 194.3 (C=O), 192.2 (C=O), 163.6 (C-4′), 161.7 (C-4′′), 137.6 (C-1), 132.0 (C-1′), 131.9 (C-1′′), 130.2 (C-4), 129.6 (C-2, C-6), 129.2 (C-3, C-5), 128.4 (C-2′, H-6′), 127.1 (C-2′′, C-6′′), 114.5 (C-3′, C-5′), 114. (C-3′′, C-5′′), 69.9 (CH~2~), 55.6 (4′′-OCH~3~); EI-MS: *m/z* (rel. abund.%), 346 \[M\]^+^ (19.9), 198 (5.9), 181 (2.1), 169 (2.1), 152 (3.4), 135 (100.0), 121 (25.0), 107 (18.5), 92 (15.9), 77 (45.7); HREI-MS: *m/z* calcd for C~22~H~18~O~4~ \[M\]^+^ 346.1205, found 346.1183.

### 4.4.17.. 2-(4-Benzoylphenoxy)-1-(4-chlorophenyl)ethanone (17) {#s4d17}

Yield: 83%; m.p. 150--152°C; R*~f~*: 0.45 (ethyl acetate/hexanes, 2:8); IR (KBr, cm^−1^): 3390 (=C--H), 1703 (C=O), 1637 (C=O), 1596 (C=C), 1315 (C--O), 1192 (=C--Cl); ^1^H-NMR (300 MHz, DMSO-*d~6~*): *δ*~H~ 8.05 (d, 2H, *J*~2,3/6,5~ = 8.7 Hz, H-2, H-6), 7.73 (m, 7H, H-4, H-2′, H-3′, H-5′, H-6′, H-3′′, H-5′′), 7.56 (t, 2H, *J*~3(2,4)/5(4,6)~ = 7.8 Hz, H-3, H-5), 7.14 (d, 2H, *J*~2′,3′/6′,5′~ = 8.4 Hz, H-2′, H-6′), 5.72 (s, 2H, CH~2~); ^13^C-NMR (75.0 MHz, DMSO-*d*~6~): *δ*~C~ 194.3 (C=O), 193.1 (C=O), 161.6 (C-4′), 138.7 (C-4′′), 137.6 (C-1), 132.9 (C-1′), 132.1 (C-1′′), 132.0 (C-4), 129.8 (C-2, C-6), 129.7 (C-3, C-5), 129.2 (C-2′, H-6′), 128.9 (C-2′′, C-6′′), 128.4 (C-3′′, C-5′′), 114.6 (C-3′, C-5′), 70.2 (CH~2~); EI-MS: *m/z* (rel. abund.%), 352 \[M + 2\]^+^ (11.7), 350 \[M\]^+^ (36.0), 211 (2.7), 198 (4.8), 181 (100.0), 151 (1.2), 105 (19.0), 77 (20.9); HREI-MS: *m/z* calcd for C~21~H~15~ClO~3~ \[M\]^+^ 350.0710, found 350.0691.

### 4.4.18.. 2-(4-Benzoylphenoxy)-1-(3,4-dichlorophenyl)ethanone (18) {#s4d18}

Yield: 81%; m.p. 142--145°C; R*~f~*: 0.45 (ethyl acetate/hexanes, 2:8); IR (KBr, cm^−1^): 3383 (=C--H), 1710 (C=O), 1628 (C=O), 1557 (C=C), 1309 (C--O); ^1^H-NMR (300 MHz, DMSO-*d~6~*): *δ*~H~ 8.26 (d, 1H, *J*~2′′,5′′~ = 1.5 Hz, H-2′′), 7.98 (dd, 1H, *J*~5′′,6′′ ~= 6.6 Hz, *J*~5′′,2′′ ~= 1.8 Hz, H-5′′), 7.88 (d, 1H, *J*~6′′,5′′~ = 8.4 Hz, H-6′′), 7.73 (d, 2H, *J*~2,3~ = *J*~6,5 ~= 8.7 Hz, H-2, H-6), 7.70 (t, 1H, *J*~4(3,5)~ = 8.7 Hz, H-4), 7.64 (d, 2H, *J*~(2′,3′)/(6′,5′)~ = 7.2 Hz, H-2′, H-6′), 7.56 (t, 2H, *J*~3(2,4)/5(4,6)~ = 8.5 Hz, H-3, H-5), 7.16 (d, 2H, *J*~3′,2′/5′,6′~ = 7.3 Hz, H-3′, H-5′), 5.74 (s, 2H, CH~2~); ^13^C-NMR (75.0 MHz, DMSO-*d*~6~): *δ*~C~ 194.4 (C=O), 193.1 (C=O), 161.6 (C-4′), 137.7 (C-3^‴^), 136.0 (C-4^‴^), 133.8 (C-1′), 133.5 (C-1), 132.1 (C-2, C-6), 132.0 (C-2′, C-6′), 130.8 (C-1^‴^), 129.8 (C-2^‴^), 129.3 (H-5′′), 128.4 (C-6^‴^), 127.7 (C-3, C-5), 126.5 (C-3′, C-5′), 114.6 (C-4), 70.3 (CH~2~); EI-MS: *m/z* (rel. abund. %), 388 \[M + 4\]^+^ (10), 386 \[M + 2\]^+^ (49), 384 \[M\]^+^ (76.2), 349 (1.9), 211 (9.2), 198 (19.1), 173 (100.0), 121 (29.9), 105 (33.6), 77 (24.0); HREI-MS: *m/z* calcd for C~21~H~14~Cl~2~O~3~ \[M\]^+^ 384.0320, found 384.0321.

### 4.4.19.. 2-(4-Benzoylphenoxy)-1-phenylethanone (19) {#s4d19}

Yield: 82%; m.p. 150--152°C; R*~f~*: 0.47 (ethyl acetate/hexanes, 2:8); ^1^H-NMR (400 MHz, DMSO-*d~6~*): *δ*~H~ 8.03 (d, 2H, *J*~2,3/6,5~ = 7.2 Hz, H-2, H-6), 7.73 (d, 2H, *J*~2′,3′/6′,5′~ = 9.2 Hz, H-2′, H-6′), 7.70 (m, 4H, H-4, H-2′′, H-4′′, H-6′′), 7.64 (d, 1H, *J*~4(3,5)~ = 7.2 Hz, H-4), 7.59 (m, 4H, H-3, H-5, H-3′′, H-5′′), 7.13 (d, 2H, *J*~3′,2′/5′,6′~ = 8.8 Hz, H-3′, H-5′), 5.74 (s, 2H, CH~2~); EI-MS: *m/z* (rel. abund. %), 316 \[M\]^+^ (41.7), 239 (1.4), 211 (1.9), 198 (4.9), 121 (5.8), 105 (100.0), 77 (20.4); HREI-MS: *m/z* calcd for C~21~H~16~O~3~ \[M\]^+^ 316.1099, found 316.1098.

### 4.4.20.. 2-(4-Benzoylphenoxy)-1-*p*-tolylethanone (20) {#s4d20}

Yield: 85%; m.p. 220--222°C; R*~f~*: 0.49 (ethyl acetate/hexanes, 2:8); ^1^H-NMR (400 MHz, DMSO-*d~6~*): *δ*~H~ 7.93 (d, 2H, *J*~2,3/6,5~ = 8.4 Hz, H-2, H-6), 7.73 (d, 2H, *J*~2′,3′/6′,5′~ = 8.8 Hz, H-2′, H-6′), 7.69 (d, 2H, *J*~3′,2′/5′,6′~ = 8.0 Hz, H-3′, H-5′), 7.64 (d, 1H, *J*~4(3,5)~ = 7.2 Hz, H-4), 7.55 (t, 2H, *J*~3(2,4)/5(4,6)~ = 7.6 Hz, H-3, H-5), 7.39 (d, 2H, *J*~3′′,2′′/5′′,6′′~ = 8.0 Hz, H-3′′, H-5′′), 7.11 (d, 2H, *J*~2′′,3′′/6′′,5′′~ = 8.8 Hz, H-2′′, H-6′′), 5.73 (s, 2H, CH~2~), 2.39 (s, 3H, CH~3~); EI-MS: *m/z* (rel. abund.%), 330 \[M\]^+^ (48.0), 253 (1.2), 198 (2.8), 181 (4.1), 152 (10.2), 119 (100.0), 105 (41.2), 91 (60.4), 77 (37.4); HREI-MS: *m/z* calcd for C~22~H~18~O~3~ \[M\]^+^ 330.1256, found 330.1255.
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